Fort Sheridan Advisors LLC Increases Stock Position in Pfizer Inc. $PFE

Fort Sheridan Advisors LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 28.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,914 shares of the biopharmaceutical company’s stock after buying an additional 25,948 shares during the period. Fort Sheridan Advisors LLC’s holdings in Pfizer were worth $2,834,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter worth about $27,000. Curio Wealth LLC boosted its stake in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares in the last quarter. Bayforest Capital Ltd bought a new position in Pfizer during the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer during the second quarter worth approximately $29,000. Finally, Evelyn Partners Asset Management Ltd bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $33,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 1.7%

PFE opened at $25.31 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The firm has a market capitalization of $143.88 billion, a price-to-earnings ratio of 13.46, a PEG ratio of 0.81 and a beta of 0.54. The business has a 50 day simple moving average of $25.03 and a two-hundred day simple moving average of $24.62.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 7th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend was Friday, November 7th. Pfizer’s dividend payout ratio is presently 100.00%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PFE. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Scotiabank started coverage on Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Bank of America boosted their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $28.39.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.